
In the latest sign of anger over the cost of insulin, the Minnesota attorney general on Tuesday filed a lawsuit accusing the three largest manufacturers — Eli Lilly, Sanofi and Novo Nordisk — with deceptively raising prices, the first state to go to court over the issue.
“Insulin is a life-or-death drug for people with diabetes,” said Minnesota Attorney General Lori Swanson in a statement. “Many people can’t afford the price hikes but can’t afford to stop taking the medication either.” As an example, the lawsuit cited the Lantus insulin sold by Sanofi, which cost $99.35 for a 10-milliliter vial in 2010, now costs $269.54.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
When I was on Medicare and a supplement insurance, I was paying $1000 a month for my insulin. Now, working for HealthPartners, I have excellent insurance and only pay $10 for a month’s worth of insulin. At $1000, I told my endocrinologist that it was either the mortgage or the insulin….I could not afford both.